Literature DB >> 8751075

Reactive red 2: a P2y-selective purinoceptor antagonist and an inhibitor of ecto-nucleotidase.

R Bültmann1, K Starke.   

Abstract

Effects of reactive red 2 and its parent compound acid red 33 were studied in rat vas deferens and guinea-pig taenia coli. In rat vas deferens, reactive red 2(1 to 10 microM) shifted the concentration-response curve for the P2X-purinoceptor-mediated contraction effect of alpha, beta-methylene ATP slightly to the right and progressively decreased the maximum (apparent antagonist Kd value 0.42 microM). Acid red 33 (1000 microM) shifted the curve to the right without changing the maximum (apparent Kd 386 microM). The concentration-contraction curve of noradrenaline was not altered by reactive red 2. In the carbachol-precontracted guinea-pig taenia coli, reactive red 2 (0.1 to 10 microM) shifted the concentration-response curve for the P2Y-purinoceptor-mediated relaxation effect of adenosine 5'-O-(2-thiodiphosphate) (ADP beta S) progressively to the right; only at the highest concentration of antagonist (10 microM) was the maximum slightly depressed; a pA2 value of 7.55 (Kd 0.028 microM) was derived from the shift. Acid red 33 (1000 microM) shifted the concentration-relaxation curve of ADP beta S to the right without changing the maximum (apparent Kd 171 microM). Reactive red 2 (1 to 10 microM) also shifted the concentration-response curve for the relaxation effect of alpha, beta-methylene ATP, which is mediated by an unclassified P2-purinoceptor, progressively to the right but simultaneously decreased the maximum (apparent Kd 1.6 microM). The concentration-relaxation curve of 2-chloroadenosine was not altered by reactive red 2. Pieces of vas deferens and taenia coli degraded 76 and 66% of added ATP (10 microM) within 30 min, respectively. Reactive red 2(0.1 to 100 microM) progressively reduced this degradation by up to 95%, with IC50 values of 3.9 +/- 0.6 and 3.9 +/- 2.3 microM, respectively. Acid red 33 (1000 microM) reduced the degradation by 30 and 20%, respectively. The results indicate that reactive red 2 is a relatively potent antagonist at both P2X-purinoceptors in rat vas deferens and P2Y-purinoceptors in guinea-pig taenia coli, with a 15 fold selectively for the P2Y-purinoceptor. It inhibits ecto-nucleotidase in both tissues. The dichloro-triazine residue that distinguishes the compound from acid red 33 greatly enhances the potency at both receptor subtypes as well as at the nucleotidase. As regards P2-purinoceptor subtypes, the results confirm the existence of two relaxation-mediating P2-purinoceptors in guinea-pig taenia coli.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8751075     DOI: 10.1007/bf00169380

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  17 in total

1.  Evaluation of P2-purinoceptor antagonists at two relaxation-mediating P2-purinoceptors in guinea-pig taenia coli.

Authors:  R Bültmann; O Dudeck; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-03       Impact factor: 3.000

2.  P2-purinoceptor antagonists discriminate three contraction-mediating receptors for ATP in rat vas deferens.

Authors:  R Bültmann; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

3.  The effects of some possible inhibitors of ectonucleotidases on the breakdown and pharmacological effects of ATP in the guinea-pig urinary bladder.

Authors:  S M Hourani; J A Chown
Journal:  Gen Pharmacol       Date:  1989

4.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

5.  Two relaxation-mediating P2-purinoceptors in guinea-pig taenia caeci.

Authors:  O Dudeck; R Bültmann; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-01       Impact factor: 3.000

6.  Blockade of P2X-purinoceptors by trypan blue in rat vas deferens.

Authors:  R Bültmann; M Trendelenburg; K Starke
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

7.  Differentiation by pyridoxal 5-phosphate, PPADS and IsoPPADS between responses mediated by UTP and those evoked by alpha, beta-methylene-ATP on rat sympathetic ganglia.

Authors:  G P Connolly
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

8.  Evans blue blocks P2X-purinoceptors in rat vas deferens.

Authors:  R Bültmann; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

9.  Blockade by 4,4'-diisothiocyanatostilbene-2,2'-disulphonate (DIDS) of P2X-purinoceptors in rat vas deferens.

Authors:  R Bültmann; K Starke
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

10.  Pharmacological analysis of ecto-ATPase inhibition: evidence for combined enzyme inhibition and receptor antagonism in P2X-purinoceptor ligands.

Authors:  B E Crack; M W Beukers; K C McKechnie; A P Ijzerman; P Leff
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

View more
  6 in total

1.  Evaluation of P2-purinoceptor antagonists at two relaxation-mediating P2-purinoceptors in guinea-pig taenia coli.

Authors:  R Bültmann; O Dudeck; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-03       Impact factor: 3.000

2.  P2-purinoceptor antagonists: II. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to Evans blue and trypan blue.

Authors:  H Wittenburg; R Bültmann; B Pause; C Ganter; G Kurz; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

Review 3.  A critical look at the function of the P2Y11 receptor.

Authors:  Karin Dreisig; Birgitte Rahbek Kornum
Journal:  Purinergic Signal       Date:  2016-05-31       Impact factor: 3.765

4.  P2-purinoceptor antagonists: I. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by small aromatic isothiocyanato-sulphonates.

Authors:  R Bültmann; B Pause; H Wittenburg; G Kurz; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

5.  Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases).

Authors:  Younis Baqi; Stefanie Weyler; Jamshed Iqbal; Herbert Zimmermann; Christa E Müller
Journal:  Purinergic Signal       Date:  2008-06-05       Impact factor: 3.765

6.  Inhibition of Ecto-Apyrase and Ecto-ATPase by Pyridoxal Phosphate-Related Compounds.

Authors:  Carsten Hoffmann; Petra Heine; Gabi Pradel; Yong-Chul Kim; Kenneth A Jacobson; Herbert Zimmermann
Journal:  Drug Dev Res       Date:  2001-01-24       Impact factor: 4.360

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.